Figure 3.

Neutralization of P.1 by mAbs

(A) Neutralization of P.1 by a panel of 20 potent human mAbs. Neutralization was measured by FRNT; curves for P.1 are superimposed onto curves for Victoria, B.1.1.7, and B.1.351 as previously reported (Supasa et al., 2021; Zhou et al., 2021). FRNT50 titers are reported in Table S2. Neutralization curves for mAbs in different stages of development for commercial use are shown.

(B) Equivalent plots for the Vir, Regeneron, AstraZeneca, Lilly, and Adagio therapeutic antibodies.